Evidence map›Paper›PMID 32447486›Full record

ArticleJournal of cancer research and clinical oncology2020

Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.

Hai-Zhen Zhu, Chun-Ju Fang, Yi Guo, Qi Zhang, Li-Min Huang, Dong Qiu, Guang-Peng Chen, Xiu-Feng Pang, Jian-Jun Hu, Jian-Guo Sun and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.Journal of experimental & clinical cancer research : CR · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hai-Zhen Zhu *Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, 550002, China.
Chun-Ju Fang *Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, 550002, China.
Yi Guo *Department of Basic Knowledge, Guiyang Nursing Vocational College, Guiyang, 400037, China.
Qi Zhang *Department of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, 550002, China.
Li-Min HuangDepartment of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, 550002, China.
Dong QiuDepartment of Oncology, Guizhou Provincial People's Hospital, Guizhou Cancer Center, Guiyang, 550002, China.
Guang-Peng ChenCancer Institute of PLA, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
Xiu-Feng PangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Jian-Jun HuDepartment of Pathology, Guizhou Provincial People's Hospital, Guiyang, 550002, China.
Jian-Guo SunCancer Institute of PLA, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. sunjg09@aliyun.com.
Zheng-Tang ChenCancer Institute of PLA, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. chenzhengtang123@163.com.ORCID http://orcid.org/0000-0002-8548-933X
Guizhou Cancer Hospital · CNArmy Medical University · CNEast China Normal University · CNGuizhou Provincial People's Hospital · CN

Funding

Gui Zhou Provincial Health and Family Planning Commission Foundation gzwjkj2017-1-002Gui Zhou Provincial Science and Technology Bureau Joint Foundation Gui Zhou LH[2016]7196the National High Technology Research and Development Program of China 2008AA02Z104the National Natural Science Foundation of China 81172070
6 · The paper itself

Abstract

purposeCurrently, the routine screening program has insufficient capacity for the early diagnosis of lung cancer. Therefore, a type of chitosan-molecular beacon (CS-MB) probe was developed to recognize the miR-155-5p and image the lung cancer cells for the early diagnosis.

methodsBased on the molecular beacon (MB) technology and nanotechnology, the CS-MB probe was synthesized self-assembly. There are four types of cells-three kinds of animal models and one type of histopathological sections of human lung cancer were utilized as models, including A549, SPC-A1, H446 lung cancer cells, tumor-initiating cells (TICs), subcutaneous and lung xenografts mice, and lox-stop-lox(LSL) K-ras G12D transgenic mice. The transgenic mice dynamically displayed the process from normal lung tissues to atypical hyperplasia, adenoma, carcinoma in situ, and adenocarcinoma. The different miR-155-5p expression levels in these cells and models were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The CS-MB probe was used to recognize the miR-155-5p and image the lung cancer cells by confocal microscopy in vitro and by living imaging system in vivo.

resultsThe CS-MB probe could be used to recognize the miR-155-5p and image the lung cancer cells significantly in these cells and models. The fluorescence intensity trends detected by the CS-MB probe were similar to the expression levels trends of miR-155 tested by qRT-PCR. Moreover, the fluorescence intensity showed an increasing trend with the tumor progression in the transgenic mice model, and the occurrence and development of lung cancer were dynamically monitored by the differen fluorescence intensity. In addition, the miR-155-5p in human lung cancer tissues could be detected by the miR-155-5p MB.

conclusionBoth in vivo and in vitro experiments demonstrated that the CS-MB probe could be utilized to recognize the miR-155-5p and image the lung cancer cells. It provided a novel experimental and theoretical basis for the early diagnosis of the disease. Also, the histopathological sections of human lung cancer research laid the foundation for subsequent preclinical studies. In addition, different MBs could be designed to detect other miRNAs for the early diagnosis of other tumors.

Indexed as

A549 CellsAnimalsChitosanEarly Detection of CancerHeterograftsHumansLung NeoplasmsMiceMice, NudeMice, TransgenicMicroRNAsMolecular ImagingMolecular ProbesNanotechnologyChitosanMicroRNAsMIRN155 microRNA, humanMolecular ProbesChitosanLung cancerMicroRNAMolecular beaconMolecular imagingTumor-initiating cell

Identifiers

PMID32447486
PMCPMC7324423
OpenAlexW3027920993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.